Ramaswamy Govindan, MD
Enriched profileAnheuser-Busch Endowed Chair in Medical Oncology; Director/Chief, Section of Medical Oncology; Associate Chief, Division of Oncology; Professor of Medicine · Washington University School of Medicine in St. Louis
Ramaswamy Govindan is Anheuser-Busch Endowed Chair in Medical Oncology; Director/Chief, Section of Medical Oncology; Associate Chief, Division of Oncology; Professor of Medicine at Washington University School of Medicine in St. Louis. OpenAlex indexes 1,247 publications with 98,957 citations (h-index 128); ClinicalTrials.gov lists 21 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Medical Oncology profiles in the findmyKOL directory.
Data verified 25 Aug 2026
Overview
Updated 27 Aug 2026
Ramaswamy Govindan, MD, is Anheuser-Busch Endowed Chair in Medical Oncology at Washington University School of Medicine in St. Louis (Division of Oncology / Siteman Cancer Center). The public record shows 1,247 publications with 98,957 citations (h-index 128), centered on Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Lung Cancer Diagnosis and Treatment. It also documents an investigator role on 21 registered clinical trials, industry payments reported by 4 companies, 10 NIH-funded awards (2010–2026).
- Most recent indexed publication: 2026 · Cancer discovery
- Top research focus: Lung Cancer Treatments and Mutations
- 21 registered trials on ClinicalTrials.gov
- Open Payments reporting from 4 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 27 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 400.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 21 registered studies on ClinicalTrials.gov. The most recent:
- DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer
Sponsor: Washington University School of Medicine
- Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)
Sponsor: Washington University School of Medicine
Industry payments
Updated 27 Aug 2026
4 companies reported payments to CMS in program years 2021–2024. These are public disclosures, not judgments. The latest:
- Genmab U.S., Inc.Program year20242 payments
- EMD Serono, Inc.Program year20221 payment
- Janssen Global Services, LLCProgram year20211 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
74.9%PD-1 inhibitor70.7%Pembrolizumab100%Part B, office-administered≥15 patientsLeukocyte Growth Factor3.6%Pegfilgrastim100%Part B, office-administered≥12 patientsSensory organs
10.7%Corticosteroid10.7%Dexamethasone sodium phosphate90%Dexamethasone10%Part D + Part B≥32 patientsMetabolism & gastrointestinal
7.8%Serotonin-3 Receptor Antagonist6.5%Palonosetron hcl91%Ondansetron Hcl6%Ondansetron Odt3%Part D + Part B<11 patientsCorticosteroid0.6%Prednisone100%Part D≥17 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
10 NIH research awards on record, funded 2010–2026 per NIH RePORTER. The latest:
- Proteogenomic Predictors of Recurrence in Non-small Cell Lung Cancer
Washington University
FY2026$1,049,939U01CA271402 - Washington University Paul Calabresi K12 Career Development Award for Clinical Oncology
Washington University
FY2026$809,998K12CA167540 - Washington University PDX Development and Trial Center
Washington University
FY2025$1,133,478U54CA224083
Congress activity
Updated 27 Aug 2026
197 congress contributions (2004–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Adjuvant erlotinib versus observation after complete resection of <i>EGFR</i> -mutant NSCLC: Final overall survival results of Alliance A081105.
ASCO Annual Meeting
ASCO2026Presenting author - Differences in central versus local lab PD-L1 classification in the ALCHEMIST Alliance A151216 non–small cell lung cancer (NSCLC) study.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Early ctDNA stratifies survival in locally advanced and oligometastatic lung cancer treated with radiotherapy.
Clinical cancer research
Article2026 - Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non-Small Cell Lung Cancer.
Clinical cancer research
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)- 01The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity2,264 citations2019
- 02Sex and gender: modifiers of health, disease, and medicine2,001 citations2020
- 03
- 04Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation1,786 citations2021
- 05KRAS <sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors1,696 citations2020
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/ramaswamy-govindan-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/Ramaswamy-Govindan-2
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - LinkedIn
linkedin.com/in/ramaswamy-govindan-04763510b
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Other
society.asco.org/people/ramaswamy-govindan-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →society.asco.org ↗ - X / Twitter
twitter.com/WashUOncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →twitter.com ↗ - Other
ilcn.org/qa-with-lead-alchemist-investigator-dr-ramaswamy-govindan
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ilcn.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncology.wustl.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncology.wustl.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncology.wustl.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗
- Co-Chair
Lung Cancer Disease Working Group, The Cancer Genome Atlas (TCGA) Project
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗ - National Study Chair/Leader
ALCHEMIST clinical trial (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.washu.edu ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →americanbazaaronline.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncology.wustl.edu ↗
Secondary affiliations
appointments beyond the home institution- Associate Director of Translational Research
Alvin J. Siteman Cancer Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →americanbazaaronline.com ↗ - Attending physician
Barnes-Jewish Hospital (Anheuser-Busch Endowed Chair held jointly with Barnes-Jewish Hospital)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.washu.edu ↗
Media & interviews
press, podcasts and appearances- "20 years of EGFR research"
panel podcast with Ramalingam, Carbone, Politi, Jänne, and Govindan, The Cancer Letter
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancerletter.com ↗ - "A Journey Through Lung Cancer History With Govindan Ramaswamy"
Healthcare Unfiltered podcast (Nov 2021), oral history of thoracic oncology
2021verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →podcasts.apple.com ↗ - Video interview: "Ramaswamy Govindan on Differences Among Male and Female Patients With Lung Cancer"
AACR Virtual Annual Meeting 2020 II, The ASCO Post
2020verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Marin Kollef, MD
Washington University School of Medicine in St. Louis
Mark Huffman, MD
Washington University School of Medicine in St. Louis
Brad Kahl, MD
Washington University School of Medicine in St. Louis
Eric Lenze, MD
Washington University School of Medicine in St. Louis